Skip to main content
Premium Trial:

Request an Annual Quote

Bionano Genomics Posts Record Revenues in Q2

NEW YORK – Bionano Genomics reported a 72 percent year-over-year growth in second quarter revenues after the close of the market on Thursday.

For the quarter ended June 30, Bionano booked $6.7 million in revenues, a record for the company, up from $3.9 million in Q2 2021 and beating the average estimate of Wall Street analysts of $6.3 million.

Of those, $3.9 million were product revenues, up from $2.5 million in Q2 2021, and $2.8 million were service and other revenues, doubling from $1.4 million in the same period a year ago.

The total installed base of Saphyr systems at the end of the quarter was 196, with 20 systems shipped in the quarter, representing a 62 percent increase compared to Q2 2021.

The company also sold 3,394 nanochannel array flow cells during the quarter, a 24 percent increase over the year-ago quarter.

Bionano's net loss for the quarter swelled to $32.2 million, compared to a net loss of $18.8 million in Q2 2021. Bionano did not report earnings per share. Analysts, on average, had expected a net loss of $.09 per share.

The firm's R&D expenses almost tripled to $11.8 million from $4.1 million a year ago, while SG&A expenses grew 58 percent to $21.8 million from $13.8 million a year ago.

As of June 30, Bionano had $27.2 million in cash and cash equivalents and $160.2 million in investments.

The company maintained its full-year revenue guidance range of $24 million to $27 million.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.